Search

Your search keyword '"Cruchaga, Carlos"' showing total 2,055 results

Search Constraints

Start Over You searched for: Author "Cruchaga, Carlos" Remove constraint Author: "Cruchaga, Carlos"
2,055 results on '"Cruchaga, Carlos"'

Search Results

1. Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia.

2. Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease

3. Genetic architecture of cerebrospinal fluid and brain metabolite levels and the genetic colocalization of metabolites with human traits

4. Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages

5. Evolution of white matter hyperintensity segmentation methods and implementation over the past two decades; an incomplete shift towards deep learning

6. Highly Accurate Disease Diagnosis and Highly Reproducible Biomarker Identification with PathFormer

7. Whole genome‐wide sequence analysis of long‐lived families (Long‐Life Family Study) identifies MTUS2 gene associated with late‐onset Alzheimer's disease

9. Rethinking the Power of Graph Canonization in Graph Representation Learning with Stability

10. Organ aging signatures in the plasma proteome track health and disease.

12. CYP1B1-RMDN2 Alzheimer’s disease endophenotype locus identified for cerebral tau PET

13. Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center

14. Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals

16. Human whole-exome genotype data for Alzheimer’s disease

17. Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease

18. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease

19. Biomarker clustering in autosomal dominant Alzheimers disease.

20. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study

21. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease

22. Autosomal dominant and sporadic late onset Alzheimer's disease share a common in vivo pathophysiology

23. CSF proteomics identifies early changes in autosomal dominant Alzheimer’s disease

24. γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)

25. Multi-ancestry GWAS reveals excitotoxicity associated with outcome after ischaemic stroke

26. Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease

27. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

28. Alzheimer’s disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals

29. Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease

30. Biobank-wide association scan identifies risk factors for late-onset Alzheimer’s disease and endophenotypes

31. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease

32. Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)

33. Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease

34. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study

35. Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimaging

36. Chronic neuropsychiatric sequelae of SARS‐CoV‐2: Protocol and methods from the Alzheimer's Association Global Consortium

37. Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome‐wide association study in over 12,000 non‐demented participants

38. Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease

41. Cell-free RNA signatures predict Alzheimer’s disease

42. Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes

43. C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts

45. Genetic variants and functional pathways associated with resilience to Alzheimer’s disease

46. Overlapping genetic architecture between Parkinson disease and melanoma

47. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology

48. Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood

49. Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer’s and coronary disease pathways

Catalog

Books, media, physical & digital resources